We looked inside some of the tweets by @dgingery and here's what we found interesting.
Inside 100 Tweets
Last Seen Profiles@UZI383@UnicornLyna@NightmaresVeng2@hotoddeok@nmhathletics@shinwa_taso@oboykin_ru@KateleenLim@BanuTaranci@rguptaji@akitacatanclub@obsesifhatus@chispina@black_out972@S_Moh43@mnnkpr
In an interview with The Center for Biosimilars, Mona Chitre, PharmD, CGP, of Excellus Blue Cross Blue Shield, says that employers are beginning to buy in around the concept of biosimilar competition. “It may take time, and it’s okay that we’re the first.” http://ow.ly/DB3a30nMF5T
This seems like a positive development for #biosimilar uptake...
Today, the FDA issued a safety announcement regarding an increased risk of mortality with a drug that is prescribed for gout. FDA is now requiring a Boxed Warning on the drug label and a new patient Medication Guide. https://go.usa.gov/xEmEa
Check this out too: #FDA Final Rule Places Six Substances On 503A Bulks List; Rejects Four
Even more Thursday reading: Patent Settlements: #FTC Gets Teva To Eschew 'No-Authorized Generic' Deals
Bonus Thursday reading: Rx Spending Growth To Be Driven By New Drug Entries, #CMS Says
More Thursday reading: Insulin Maker Lilly Seeks US #FDA Assurances On ‘Authorized Biologics’
Thursday morning reading: Pediatric Exclusivity For ‘Deemed’ Biologics Needs Clarity, Industry Tells US #FDA
My colleagues at @HBWInsight are working on this now...
It is one week to go until our industry analysts discuss their data-based views on what is in-store for key drugs in 2019! Join us next week http://bit.ly/2sWVVS2
Check this out...
And this...How One Biotech Venture Is Breaking The Cost Barrier In Manufacturing MAbs For Infectious Diseases
Check this out too: Can Government Petition PTAB To Review Patents? Supreme Court Seems Skeptical
Here's part 1 in case you missed it:
Part 2 of our story on the #FDA competitive generic therapy guidance:
More Wednesday reading: Annuity Payment Model For Cures May Get Test Drive In Massachusetts
Snow day reading: Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials
A @PharmaPinkSheet analysis of #FDA data found that most biosimilar AEs being reported using brand name: https://pink.pharmaintelligence.informa.com/PS124042/Biosimilar-Suffixes-Appear-Superfluous-In-Adverse-Event-Reporting …
This Administration is expediting the review and approval of generic drugs in order to deliver real price reductions and better healthcare access to American patients.
#SupremeCourt denies Frosh v. AAM cert petition challenging 4th Circuit ruling that Maryland's Anti-Price Gouging Act violates Constitution's Commerce clause, and denies Mylan v. UCB petition seeking review of Federal Circuit's approach to obviousness-type double-patenting $MYL
Check this out...